Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Total Non-Current Liabilities (2019 - 2023)

Marker Therapeutics (MRKR) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $2.9 million as the latest value for Q2 2023.

  • On a quarterly basis, Total Non-Current Liabilities fell 73.0% to $2.9 million in Q2 2023 year-over-year; TTM through Jun 2023 was $2.9 million, a 73.0% decrease, with the full-year FY2022 number at $7.0 million, down 37.42% from a year prior.
  • Total Non-Current Liabilities was $2.9 million for Q2 2023 at Marker Therapeutics, down from $6.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $11.9 million in Q3 2020 to a low of $226111.0 in Q1 2020.
  • A 5-year average of $7.0 million and a median of $8.1 million in 2020 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: surged 5083.22% in 2021, then crashed 73.0% in 2023.
  • Marker Therapeutics' Total Non-Current Liabilities stood at $280247.0 in 2019, then skyrocketed by 4134.99% to $11.9 million in 2020, then fell by 5.23% to $11.2 million in 2021, then crashed by 37.42% to $7.0 million in 2022, then plummeted by 58.51% to $2.9 million in 2023.
  • Per Business Quant, the three most recent readings for MRKR's Total Non-Current Liabilities are $2.9 million (Q2 2023), $6.8 million (Q1 2023), and $7.0 million (Q4 2022).